FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the ...

Kangpu Biopharmaceuticals, Ltd. ('Kangpu') today announced that the Company has received IND approval from the CDE (Center ...

Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...

Health care providers can now administer Sublocade subcutaneously into the thigh, buttock, or the back of the upper arm, in addition to the abdomen.

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy ...

Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today announced that the first patient has been dosed in the clinical trial of IB-T101, the company's ...

PMN310 is a humanized monoclonal antibody (mAb) designed and developed to selectively target only soluble amyloid-beta ...

The US Food and Drug Administration (FDA) has approved label changes for Sublocade (buprenorphine extended-release), ...

Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...

The main growth driver for Alkermes going forward will be ALKS 2680. Read why I maintain my buy rating on ALKS stock.

”Following the promising results from the first part of the phase 1b/2a study, we are pleased to see our portfolio company AnaCardio advancing the clinical development of AC01 by initiating the second ...

If you’ve been wanting to add a retinol into your skin care routine but don’t know where to start, we tapped a few experts ...